PubMed Health⌕ Search

Biomedical subjects

S Moolgavkar

Publications and source records attributed to S Moolgavkar.

10 recordsLinked to original sources

Quantitative analysis of tumor initiation in rat liver: role of cell replication and cell death (apoptosis).

The formation and development of initiated cells has been studied at the beginning of hepatocarcinogenesis. Rats received the genotoxic carcinogen N-nitrosomorpholine (NNM); placental glutathione S-transferase was used as a marker of initiated cells (G+ cells). Single G+ cells appeared within 24 h after NNM; their frequency increased steeply for approximately 2 weeks, then decreased and finally remained constant. G+ foci consisting of >/=2 G+ cells appeared successively after the single cells. Histological determination of DNA replication and apoptosis revealed that: the formation of single G+ cells may not depend on DNA replication of precursor cells; single G+ cells showed considerably lower DNA replication than G- normal hepatocytes; from the 2-cell stage onwards G+ foci displayed enhanced DNA replication and apoptosis. Data from histological sections were transformed into the third dimension by a new stereological method which considers the non-spherical shape of many G+ lesions. Rates of division and death of G+ cells and of formation and growth of G+ foci were estimated by a stochastic model: initially G+ clones appeared at a rate of 12 000 per day and liver until a maximal number of 176 000 (phase I) was reached; thereafter they declined to 134 000 (phase II); they then remained constant (phase III). Estimated division rates of G+ cells decreased from phase I to phase III, while the death rate increased in phase II, when every third G+ clone disappeared. As a result, at day 50 after NNM only 0.3% of G+ single cells had formed a clone containing >/=5 cells. In conclusion, experimental and computed parameters provide direct evidence that hepatocarcinogenesis evolves clonally and that initiated hepatocytes have a selective proliferation advantage, associated with an enhanced potential to undergo apoptosis. Thereby, depending on the conditions, initiated clones expand or become extinct. Extinction may lead to reversion of the biological effects of initiation.

Animals↗

Role of receptors in human and rodent hepatocarcinogenesis.

The liver is a major target organ in rodent carcinogenicity assays. Amongst the agents that are effective in producing rodent liver tumours are many chemicals which are not mutagenic, but are believed to mediate their effects by promoting the clonal outgrowth of initiated cells. Some of these chemicals, such as dibenzo-p-dioxins and certain PCBs, have been demonstrated to interact with specific cellular receptors and receptor binding appears crucial for their tumourigenic activity. Enzyme-altered foci in rat liver may serve as a sensitive means to estimate the promoting activity of these agents in rodents. Mechanistic considerations are of relevance when extrapolating these data from rodents to humans.

Animals↗

Myeloid leukaemia following therapy for a first primary cancer.

To evaluate the risk of second primary myeloid leukaemia due to radiotherapy and chemotherapy administered for a first primary cancer, we conducted a population-based case-control study consisting of 97 cases and 194 controls matched on age, date of diagnosis, and site of initial primary cancer among residents of 13 counties in western Washington State. The risk of myeloid leukaemia in patients who received cyclophosphamide as part of their chemotherapy regimen was 7.4 (95% confidence interval 1.3-43.8). This risk was not altered appreciably by the administration of radiotherapy. Compared to patients not receiving any chemotherapy, the relative risk among patients who received prednisone in combination with cyclophosphamide (odds ratio 44.4 95% confidence interval 4.0-496.2) was nearly four times that among patients receiving cyclophosphamide without this steroid (odds ratio 12.6 95% confidence interval 2.4-64.9). The relative risk of second primary myeloid leukaemia in patients who received both prednisone and drugs other than cyclophosphamide (odds ratio 64.2 95% confidence interval 2.6-1582) was 20 times that among patients receiving drugs other than cyclophosphamide and no prednisone (odds ratio 3.2 95% confidence interval 0.6-16.9). These risk estimates were higher when the analysis was restricted to acute myeloid leukaemia. There was no increased risk of second primary myeloid leukaemia associated with radiotherapy. The single unique finding is that the use of prednisone in chemotherapy regimens may enhance the leukaemogenic effect of other chemotherapy drugs.

Acute Disease↗